Press Release

December 5, 2019

Engage Therapeutics Announces Two Poster Presentations at the American Epilepsy Society’s Annual Meeting

Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing an orally inhaled benzodiazepine for the acute termination of an ongoing prolonged focal, generalized or cluster seizure episode […]
November 12, 2019

Engage Therapeutics to Present at the Stifel 2019 Healthcare Conference

Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing an orally inhaled benzodiazepine for the acute termination of an ongoing prolonged focal, generalized or cluster seizure episode […]
September 9, 2019

Engage Therapeutics to Present at the 21st Annual H.C. Wainwright Global Investment Conference

SUMMIT, N.J., Sept. 9, 2019 /PRNewswire/ — Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing an inhaled benzodiazepine for the abortive treatment of seizures in patients […]
August 14, 2019

Proof of Concept trial results for Staccato Alprazolam has neurology community cautiously optimistic

Speed of onset action is encouraging; additional research on other epilepsy patient subsets an important next step. Read more here: https://journals.lww.com/neurotodayonline/Pages/articleviewer.aspx?year=2019&issue=08080&article=00009&type=Fulltext